Taking tenofovir/emtricitabine (Truvada) as pre-exposure prophylaxis (PrEP) has little effect on kidney function, according to a study recently published in AIDS. The study, known as IPrEx (Iniciativa Profilaxis Pre-Exposicion), showed a very mild decrease in creatinine clearance (CrCl)—a measure of kidney function—among participants taking Truvada, but the change was reversible, as CrCl returned to baseline levels after the drug was discontinued at the end of the study.
The new technique uses genetic modification of cells — not drugs — to treat HIV.
Lack of health insurance, incarceration and partner choice all implicated as causes
BOSTON — Researchers are reporting that injections of long-lasting AIDS drugs protected monkeys for weeks against infection, a finding that could lead to a major breakthrough in preventing the disease in humans.
A team of UCLA researchers have found that Twitter as well as other real-time social media tools can be extremely useful in tracking outbreaks of HIV and drug use